文献速递瓣膜病与结构性心脏病心律失常

TAVI术后直接口服抗凝药与维生素K拮抗剂的比较

Direct oral anticoagulants versus vitamin K antagonist after transcatheter aortic valve implantation.
PubMed 文献 · Heart · 2023-10-26

基于德国主动脉瓣注册研究(GARY)的前瞻性多中心数据,分析45 598例TAVI患者中16 974例接受口服抗凝治疗者的1年结局。倾向调整后,DOAC与VKA在全因死亡及心脑血管事件复合终点上无显著差异,支持DOAC在TAVI术后有抗凝指征患者中的有效性。

要点

  • TAVI术后有口服抗凝指征者中,VKA占66.8%,DOAC占33.2%,DOAC使用率从2011年9.4%升至2019年69.9%。
  • 调整混杂后,DOAC与VKA在全因死亡(HR 0.95,95%CI 0.88–1.01,p=0.114)上无显著差异。
  • 心脑血管事件复合终点(HR 0.93,95%CI 0.86–1.01,p=0.071)两组间亦无显著差异。

核心结论

  • 在TAVI术后有口服抗凝指征的患者中,DOAC与VKA在1年全因死亡及心脑血管事件复合终点上无显著差异。

研究设计与样本

  • 分析对象为45 598例TAVI患者(平均年龄80.7±5.7岁,男性49.3%),其中16 974例(37.2%)出院时接受含VKA或DOAC的抗凝方案。

主要发现

  • 接受抗凝治疗者中VKA 11 333例(66.8%),DOAC 5 641例(33.2%),DOAC使用率从2011年9.4%增至2019年69.9%。
  • 1年随访每100人年的全因死亡与心脑血管事件复合终点绝对事件率:VKA组分别为1.9和1.3,DOAC组分别为1.7和1.2。
  • 调整基线混杂后,全因死亡(HR 0.95,95%CI 0.88–1.01,p=0.114)与心脑血管事件无生存(HR 0.93,95%CI 0.86–1.01,p=0.071)在VKA与DOAC组间无显著差异。

临床怎么用

  • TAVI术后合并口服抗凝指征的患者,可考虑使用DOAC作为VKA的替代选择。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: After transcatheter aortic valve implantation (TAVI), the optimal regimen of anticoagulant therapy in patients with an additional indication for oral anticoagulation remains a matter of debate. This study investigates the efficacy of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) in patients after TAVI in a real-world population. METHODS: The German Aortic Valve RegistrY (GARY) is a prospective, multicentre registry enrolling patients undergoing invasive treatment for aortic valve disease. From January 2011 to December 2019, 1 41 790 patients from 92 hospitals in Germany were enrolled. Anticoagulatory treatment regimens were assessed at hospital discharge for patients after TAVI procedures. All-cause mortality and the combined endpoint 'cardiac and cerebrovascular events' containing myocardial infarction, stroke, transient ischaemic attack, aortic prosthesis reintervention and all-cause mortality in the first year after TAVI were examined by treatment regimen. RESULTS: Of 45 598 patients (mean age 80.7±5.7 years, 49.3% males) undergoing TAVI, 16 974 patients (37.2%) received an anticoagulant regimen that included VKA or DOAC. Hereof, the majority of patients were prescribed VKA (n=11 333, 66.8%) compared with DOAC (n=5641, 33.2%) with an increase of DOAC use from 9.4% in 2011 to 69.9% in 2019. During the 1-year follow-up, the absolute event rates per 100 person-years for all-cause mortality and the combined endpoint cardiac and cerebrovascular events were 1.9 and 1.3 for VKA-treated and 1.7 and 1.2 for DOAC-treated patients, respectively. After adjustment for baseline confounders, all-cause mortality (HR 0.95, 95% CI 0.88 to 1.01, p=0.114) and cardiac and cerebrovascular event-free survival (HR 0.93, 95% CI 0.86 to 1.01, p=0.071) did not differ significantly between VKA and DOAC groups. CONCLUSIONS: This study supports evidence of the efficacy of DOAC use after TAVI in patients with an indication for oral anticoagulation.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Hohmann C, Pfister R, Frerker C, et al. Direct oral anticoagulants versus vitamin K antagonist after transcatheter aortic valve implantation. Heart. 2023. PMID: 37407220. doi:10.1136/heartjnl-2023-322548

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。